Ken-ichi Miyamoto

Title: Ken-ichi Miyamoto: Innovator in Enzyme Replacement Therapy

Introduction

Ken-ichi Miyamoto is a notable inventor based in Kanazawa, Japan. He has made significant contributions to the field of enzyme replacement therapy, particularly in the treatment of hypophosphatasia. His innovative work has led to the development of new compositions and methods that enhance therapeutic options for patients suffering from this condition.

Latest Patents

Ken-ichi Miyamoto holds 2 patents related to compositions and methods for treating hypophosphatasia. His latest patents focus on enzyme replacement therapy, where he discloses a method for producing membrane-bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. Specifically, he has developed a soluble active form of the membrane-bound enzyme TNSALP by deleting the GPI anchor single peptide sequence. This composition has shown promise in treating hypophosphatasia, and he has also disclosed oligo acid amino acid variants that specifically target bone tissue.

Career Highlights

Throughout his career, Ken-ichi Miyamoto has worked with esteemed institutions such as Saint Louis University and Shimane University. His research has significantly advanced the understanding and treatment of hypophosphatasia, making him a key figure in this area of study.

Collaborations

Ken-ichi has collaborated with notable individuals in his field, including Shunji Tomatsu and William S. Sly. These collaborations have further enriched his research and contributed to the development of innovative therapeutic methods.

Conclusion

Ken-ichi Miyamoto's contributions to enzyme replacement therapy exemplify the impact of innovative research in medicine. His work continues to pave the way for new treatments that can improve the quality of life for patients with hypophosphatasia.